-
01:59:33 PM

BMY Stock News

09/26/23 6:59 AM
NYSE : BMY
conferencesearnings
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
Bristol Myers Squibb will announce results for the third quarter of 2023 on Thursday, October 26, 2023. Those unable to register can access the live conference call by dialing in the U.S. toll free 1-833-816-1116 or international +1 412-317-0705. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference...
RHEA-AI
neutral
09/22/23 6:59 AM
NYSE : BMY
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb today announced the Phase 3 CheckMate -77 T trial met its primary endpoint of improved event-free survival as assessed by Blinded Independent Central Review in patients with resectable stage IIA to IIIB non-small cell lung cancer. In a prespecified interim analysis, the perioperative regimen of neoadjuvant Opdivo with chemotherapy...
RHEA-AI
negative
09/14/23 8:30 AM
NYSE : BMY
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
Bristol Myers Squibb is today holding a Research and Development Day in New York to discuss the company’ s R&D strategy and capabilities and to provide insight into its robust pipeline supporting long-term sustainable growth. Members of the company’ s leadership team will also highlight its differentiated research platforms and enhanced R&D framework,...
RHEA-AI
neutral
09/11/23 6:59 AM
NYSE : BMY
clinical trial
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Bristol Myers Squibb today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo plus Yervoy compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression levels.
RHEA-AI
negative
09/09/23 6:01 PM
NYSE : BMY
clinical trial
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
Bristol Myers Squibb today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist in patients with progressive pulmonary fibrosis. The study showed that twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted...
RHEA-AI
neutral
09/07/23 7:00 AM
NYSE : BMY
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
With cancer patients top of mind, teams of Bristol Myers Squibb employees will celebrate a decade of Coast 2 Coast 4 Cancer this year and cycle nearly 3,000 miles from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research. Since its inception in 2014, Bristol Myers Squibb employees– who have all been personally...
RHEA-AI
positive
09/01/23 6:59 AM
NYSE : BMY
conferences
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Bristol Myers Squibb today announced that the company will participate in the Morgan Stanley 21 st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Giovanni Caforio, M.D., board chair and chief executive officer, and Chris Boerner, Ph.D., executive vice president and chief operating officer, will answer questions about the...
RHEA-AI
neutral
08/28/23 10:00 PM
NYSE : BMY
fda approval
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has approved Reblozyl ® for the treatment of anemia without previous erythropoiesis stimulating agent use in adult patients with very low- to intermediate-risk myelodysplastic syndromes who may require regular red blood cell transfusions. This expanded indication to the...
RHEA-AI
neutral